Travere Therapeutics Provides Corporate Update and 2025 Outlook
January 13, 2025 07:00 ET
|
Travere Therapeutics, Inc.
Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA...
Magna International Inc. Announces Date for Q4 & Year End 2024 Results and 2025 Outlook Webcast
January 08, 2025 08:00 ET
|
Magna International Inc.
AURORA, Ontario, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Magna International Inc. (TSX:MG) (NYSE:MGA) MAGNA INTERNATIONAL INC. ANNOUNCES DATE FOR Q4 & YEAR END 2024 RESULTS and 2025 OUTLOOK...